Novartis Signs 250 Million-Dose Vaccine Pact With CureVac
- Swiss pharma giant is in talks on more Covid partnerships
- Novartis to make up to 50 million doses for CureVac this year
Source: CureVac
This article is for subscribers only.
Novartis AG agreed to produce CureVac NV’s Covid-19 vaccine candidate in a deal that will boost the potential supply of the shot by as much as 250 million doses over the course of this year and next.
The Swiss pharmaceutical giant could make as many as 50 million doses this year and 200 million doses in 2022, the partners said in a statement. Once the final agreement is signed, Novartis plans to start production in the second quarter and ship the first deliveries to CureVac this summer.